applied dna sciences faces nasdaq delisting due to bid price rule

Applied DNA Sciences (APDN) initially received a Nasdaq non-compliance notification due to its stock price remaining below $1.00 for 32 consecutive days, prompting a 1-for-15 reverse stock split. While the company requested a hearing to avoid potential delisting, it has since regained compliance with Nasdaq's minimum bid price requirement by maintaining a price of $1.00 or more for 16 consecutive business days; APDN has also focused on securing a U.S.-based supply chain and refining its pharmacogenomics strategy.

Analysis

Applied DNA Sciences (APDN) recently addressed a Nasdaq non-compliance issue concerning its minimum bid price. After its stock traded below $1.00 for 32 consecutive business days (April 14 - May 29, 2025), the company executed a 1-for-15 reverse stock split on June 2, 2025. Although initially ineligible for an automatic cure period due to prior splits and thus requesting a Nasdaq hearing to appeal a potential delisting, APDN subsequently regained compliance by maintaining a closing bid price of at least $1.00 for 16 consecutive business days. This restored compliance is vital for the company, currently trading at $5.50 with a $2.42 million market capitalization. Strategically, APDN's subsidiary, LineaRx, secured a U.S.-based supply chain for key materials, aligning with the BIOSECURE Act of 2024, and its clinical laboratory arm refined its pharmacogenomics strategy for its TR8™ PGx testing service. Despite these positive steps and a strong current ratio of 4.45x indicating robust liquidity, InvestingPro data highlights that the company faces 'significant operational challenges'.

Key Decisions for Investors

• Investors should note that Applied DNA Sciences' regained Nasdaq compliance, achieved through a 1-for-15 reverse stock split, mitigates immediate delisting risk though the company still contends with 'significant operational challenges' despite strong liquidity (current ratio 4.45x), the strategic initiatives such as securing a U.S. supply chain and enhancing pharmacogenomics offerings present potential long-term catalysts whose successful execution is critical for the micro-cap company, investors should be prepared for high stock price volatility given APDN's very small market capitalization ($2.42 million) and recent reverse stock split, and continued monitoring of sustained Nasdaq compliance, progress on strategic goals, and clarification of operational challenges is warranted.